Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
Status:
Terminated
Trial end date:
2021-03-03
Target enrollment:
Participant gender:
Summary
This is an open-label, prospective, randomized, controlled, parallel group, multi-center
phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with
recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of
platinum-based reinduction therapy and with no clinical benefit.